The Zacks Analyst Blog Highlights Amazon.com, Salesforce, Abbott Laboratories and Fossil Group

For Immediate ReleaseChicago, IL – August 21, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amazon.com, Inc. AMZN, Salesforce, Inc. CRM, Abbott Laboratories ABT and Fossil Group, Inc. FOSL.Here are highlights from Wednesday’s Analyst Blog:Top Research Reports for Amazon, Salesforce and AbbottThe Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc., Salesforce, Inc. and Abbott Laboratories, as well as a micro-cap stock Fossil Group, Inc. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.You can see all of today’s research reports here >>>Ahead of Wall StreetThe daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.You can read today's AWS here >>> Rotation Continues on Big Morning for Retail EarningsToday's Featured Research ReportsShares of Amazon.com have gained +3% over the year-to-date period against the Zacks Internet - Commerce industry’s gain of +11.8%. The company reported strong second-quarter results with revenues and earnings beating estimates. Top-line gained from solid growth across North America, International, and AWS segments.Strengthening its AWS services portfolio and its growing adoption rate contributed well to AWS performance which grew 17.5% to $30.8 billion. Ultrafast delivery services and expanding content portfolio were beneficial. Strengthening relationships with third-party sellers was a positive. Robust advertising business contributed well. Prime services showed robust momentum with 12% growth.However, the stock fell 7% after-hours due to weaker Q3 operating income guidance of $15.5-20.5 billion and concerns about margin pressure from heavy AI investments totaling $100+ billion in capital expenditure plans.(You can read the full research report on Amazon.com here >>>)Salesforce has underperformed the Zacks Computer - Software industry over the year-to-date period (-26.2% vs. +17.3%). The company is facing stiff competition and unfavorable currency fluctuations are concerns. Softening IT spending amid ongoing macroeconomic uncertainties may hurt its growth prospects.Nevertheless, Salesforce is benefiting from a robust demand environment as customers are undergoing a major digital transformation. Its sustained focus on aligning products with customer needs is driving the top line. Continued deal wins in the international market are another growth driver. The buyout of Slack has positioned it as a leader in enterprise team collaboration and improved its competitive standing compared to Microsoft Teams.Salesforce’s strategy of continuous expansion of generative AI offerings will help it tap the growing opportunities in the space. The Zacks analyst estimates suggest that Salesforce revenues are expected to witness a CAGR of 9.1% through fiscal 2025-2028.(You can read the full research report on Salesforce here >>>)Shares of Abbott have outperformed the Zacks Medical - Products industry over the past year (+22.3% vs. +6%). The company’s strong pipeline is opening up new growth opportunities, supporting the company’s positive momentum and strong growth outlook for 2025. Freestyle Libre, Lingo and Libre Rio CGM devices are on a great trajectory.Alinity, the company’s next-generation suite of systems, is a key driver in the core lab diagnostics business. The company is optimistic about its latest progress with biosimilars and expects this to significantly boost EPD sales through 2025. Within Nutrition, despite softness in international pediatric arm, Abbott is regaining market share banking on strong Adult Nutrition business.Yet, the significant runoff of COVID-19 testing-related sales is hurting Abbott’s Diagnostics growth. Headwinds such as tough macro conditions, tariffs and foreign exchange also add to the worry.(You can read the full research report on Abbott here >>>)Fossil’s shares have outperformed the Zacks Retail - Apparel and Shoes industry over the year-to-date period (+86.9% vs. -12.7%). This microcap company with market capitalization of $169.96 million has strengthened its balance sheet via a $150 million revolver due 2030 and debt exchange extending maturities to 2029, reducing refinancing risk and enhancing liquidity.Despite a 16% sales decline in Q2 2025, gross margins rose to 57.5% and adjusted operating income reached $4 million, reflecting cost discipline, reduced promotions and channel optimization. Management guides for further margin gains as SG&A savings and licensing efficiencies take hold. Digital-first strategies — including influencer-led campaigns and full-price e-commerce — are boosting traffic and profitability.The turnaround plan targets $30 million in FY25 savings through supply chain, pricing and vendor initiatives. However, revenue contraction, weak demand in Europe/China, tariff headwinds and intense competition pose risks. Valuation remains compelling at 0.21X EV/sales and 1.27X P/B against industry/sector multiples.(You can read the full research report on Fossil here >>>)Why Haven't You Looked at Zacks' Top Stocks?Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.Today you can access their live picks without cost or obligation.See Stocks Free >>Zacks Investment Research800-767-3771 ext. 9339support@zacks.comhttps://www.zacks.comPast performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.Free Report: 3 Software Stocks Poised to SkyrocketSoftware stocks are poised to catapult higher in the coming months (and years) thanks to several factors, especially the explosive growth of AI. Zacks' urgent report reveals 3 top software stocks to own right now.Access the report free today >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amazon.com, Inc. (AMZN): Free Stock Analysis Report Abbott Laboratories (ABT): Free Stock Analysis Report Salesforce Inc. (CRM): Free Stock Analysis Report Fossil Group, Inc. (FOSL): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks